|Other Accession||P70193, NP_056356.2|
|Other Names||Leucine-rich repeats and immunoglobulin-like domains protein 1, LIG-1, LRIG1, LIG1|
|Target/Specificity||The synthetic peptide sequence is selected from aa 816-829 of HUMAN LRIG1|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.|
|Cellular Location||Cell membrane; Single-pass type I membrane protein|
|Tissue Location||Widely expressed.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
LRIG1 act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.
Rose, J. Phd, et al. Mol. Med. (2010) In press :
Ye, F., et al. J. Neurooncol. 94(2):183-194(2009)
Ljuslinder, I., et al. Breast Cancer Res. 11 (3), 403 (2009) :
Miller, J.K., et al. Cancer Res. 68(20):8286-8294(2008)
Stutz, M.A., et al. Oncogene 27(43):5741-5752(2008)
If you have any additional inquiries please email technical services at email@example.com.